Module CC-14 · Version 1.0
Serial Cardiac Biomarkers and Myocardial Injury
Work through how to read serial high-sensitivity cardiac troponin (hs-cTn) results: what the assay-specific 99th-percentile upper reference limit (URL) means, how a rise or fall pattern distinguishes acute from chronic myocardial injury, how the ESC 0h/1h sampling algorithm classifies a patient into rule-out, observe, or rule-in zones, and how to recognize nonischemic causes and analytical interferents such as macrotroponin before a discordant result is escalated.
Your next section
Start section 1Read without an account. Sign in to save.
Who this module is for
Clinical laboratory scientists and trainees who release and interpret cardiac troponin results and need to reason about serial patterns, assay-specific decision limits, and interferences without diagnosing infarction from laboratory data alone.
Learning objectives
- Distinguish myocardial injury, defined by a troponin value above the assay-specific 99th-percentile URL, from a specific clinical cause of that injury
- Explain why serial sampling and the pattern of change, not a single value, separate acute from chronic myocardial injury
- Recognize assay-specific 99th-percentile limits, sex-specific reporting where adopted, renal and other chronic elevations, macrotroponin, and immunoassay interference as factors that change how a troponin result should be read
How completion works
Mark every required section done and answer every knowledge check in those sections correctly. The final save completes the module automatically.
Sources
14 sources
1. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-2264.
Source note · consensus standard
2. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826, including online supplementary assay-specific cutoff tables.
Source note · professional society guidance
3. US FDA. 510(k) clearance documentation, Elecsys Troponin T Gen 5 STAT, K162895 (with related K201441 summary).
Source note · manufacturer labeling
4. Roche Diagnostics. Elecsys Troponin T hs STAT method sheet, v3.0, February 2024.
Source note · manufacturer labeling
5. Roche Diagnostics. Elecsys Troponin T hs Gen 6, product method documentation.
Source note · manufacturer labeling
6. Role of Antitroponin Antibodies and Macrotroponin in the Clinical Interpretation of Cardiac Troponin. PMC11255741.
Source note · peer-reviewed literature
7. Macrotroponins cause discrepancy in high-sensitivity examination. PubMed 36628561.
Source note · peer-reviewed literature
8. Clinical and Laboratory Standards Institute. EP07 - Interference Testing in Clinical Chemistry. 3rd ed. CLSI; 2018, reaffirmed 2022; EP07 Plus practice guide, March 2026.
Source note · consensus standard
9. Cardiac troponins and chronic kidney disease. Kidney Int. 2006.
Source note · peer-reviewed literature
10. 42 CFR 493.1291, Standard: Test report (post-analytic systems, CLIA).
Source note · federal regulation
11. College of American Pathologists. All Common Checklist, COM.30000 Critical Result Notification (Phase II). CAP Accreditation Program, 12.09.2025 edition.
Source note · accreditation standard
12. IFCC Committee on Clinical Applications of Cardiac Bio-Markers. Cardiac Troponin Assay Interference Table (Hemolysis and Biotin), v012026.
Source note · professional society guidance
13. Effect of Sample Hemolysis on Cardiac Troponin I and T Assays. Clin Chem. 2010;56(8):1357-1364.
Source note · peer-reviewed literature
14. Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of AACC and the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers. Clin Chem. 2018.
Source note · professional society guidance